|
Volumn 17, Issue 1, 2002, Pages 33-38
|
Treatment of Leber's hereditary optic neuropathy: Theory to practice
|
Author keywords
Antioxidants; Apoptosis; Glaucoma; Leber's hereditary optic neuropathy; Mitochondrial DNA
|
Indexed keywords
ACETYLCYSTEINE;
ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
ANTICONVULSIVE AGENT;
ANTIOXIDANT;
BRIMONIDINE;
CREATINE;
CYCLOSPORIN A;
GENE PRODUCT;
MEMANTINE;
MITOCHONDRIAL DNA;
MODAFINIL;
MONOAMINE OXIDASE INHIBITOR;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
NEUROPROTECTIVE AGENT;
SELEGILINE;
TOPIRAMATE;
UBIQUINONE;
ANTIOXIDANT ACTIVITY;
APOPTOSIS;
CLINICAL TRIAL;
GENE MUTATION;
GENETIC COUNSELING;
GENETIC DISORDER;
GENOME;
GLAUCOMA;
HEREDITARY OPTIC ATROPHY;
HUMAN;
HUMAN CELL;
MITOCHONDRION;
NARCOLEPSY;
NEUROPROTECTION;
OPTIC NERVE DISEASE;
OXIDATIVE STRESS;
PARKINSON DISEASE;
PATHOPHYSIOLOGY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RETINA GANGLION CELL;
REVIEW;
VISUAL IMPAIRMENT;
DNA, MITOCHONDRIAL;
GENETIC PREDISPOSITION TO DISEASE;
HUMANS;
OPTIC ATROPHY, HEREDITARY, LEBER;
POINT MUTATION;
|
EID: 0036492205
PISSN: 08820538
EISSN: None
Source Type: Journal
DOI: 10.1076/soph.17.1.33.10288 Document Type: Review |
Times cited : (9)
|
References (26)
|